Ets-2 and p160 proteins collaborate to regulate c-Myc in endocrine resistant breast cancer

被引:53
作者
Al-Azawi, D. [1 ,2 ]
Mc Ilroy, M. [1 ]
Kelly, G. [3 ]
Redmond, A. M. [1 ]
Bane, F. T. [1 ]
Cocchiglia, S. [1 ]
Hill, A. D. K. [1 ]
Young, L. S. [1 ]
机构
[1] Royal Coll Surgeons Ireland, Dept Surg, Dublin 2, Ireland
[2] Univ Coll Dublin, Sch Med & Med Sci, UCD Conway Inst, Dublin 2, Ireland
[3] Univ Coll Dublin, Sch Math Sci Stat & Actuarial Sci, Dublin 2, Ireland
关键词
breast cancer; myc; SRC-1; tamoxifen resistance; Ets-2;
D O I
10.1038/sj.onc.1210964
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Associations between p160 coactivator proteins and endocrine resistance have been described. Though thought to primarily interact with steroid receptors, the p160 proteins can also interact with non-nuclear receptor transcription factors including the MAP kinase effector proteins Ets. Here, we observed that in breast cancer cells resistant and insensitive to endocrine treatment, the growth factor EGF induced Ets-2 but not Ets-1 transcriptional regulation of the oncogene myc. Ets-2 regulation of myc was found to be reliant on the p160 proteins SRC-1 and SRC-3. In support of these molecular observations, strong associations were observed between the transcription factor, Ets-2 and its coactivator SRC-1 (P < 0.01) and the target gene myc (P < 0.0001) in a cohort of breast cancer patients with locally advanced disease. Expression of Ets-2, SRC-1 and c-Myc individually all associated with reduced disease-free survival (P < 0.001, P < 0.001 and P = 0.002 respectively). There was no association between SRC-3 and disease-free survival (P = 0.707). SRC-1 can utilize MAP kinase effector transcription factor Ets-2 to regulate the production of the oncogene myc. These signalling mechanisms maybe important in the development of steroid resistant/independent breast cancer.
引用
收藏
页码:3021 / 3031
页数:11
相关论文
共 27 条
  • [11] Oncogenic Neu/ErbB-2 increases ets, AP-1, and NF-kappa B-dependent gene expression, and inhibiting ets activation blocks neu-mediated cellular transformation
    Galang, CK
    GarciaRamirez, JJ
    Solski, PA
    Westwick, JK
    Der, CJ
    Neznanov, NN
    Oshima, RG
    Hauser, CA
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (14) : 7992 - 7998
  • [12] Concerted activation of ETS protein ER81 by p160 coactivators, the acetyltransferase p300 and the receptor tyrosine kinase HER2/Neu
    Goel, A
    Janknecht, R
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (15) : 14909 - 14916
  • [13] The Myc/Max/Mad network and the transcriptional control of cell behavior
    Grandori, C
    Cowley, SM
    James, LP
    Eisenman, RN
    [J]. ANNUAL REVIEW OF CELL AND DEVELOPMENTAL BIOLOGY, 2000, 16 : 653 - 699
  • [14] Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells
    Hutcheson, IR
    Knowlden, JM
    Madden, TA
    Barrow, D
    Gee, JMW
    Wakeling, AE
    Nicholson, RI
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2003, 81 (01) : 81 - 93
  • [15] p300/cAMP-responsive element-binding protein interactions with Ets-1 and Ets-2 in the transcriptional activation of the human stromelysin promoter
    Jayaraman, G
    Srinivas, R
    Duggan, C
    Ferreira, E
    Swaminathan, S
    Somasundaram, K
    Williams, J
    Hauser, C
    Kurkinen, M
    Dhar, R
    Weitzman, S
    Buttice, G
    Thimmapaya, B
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (24) : 17342 - 17352
  • [16] MCIIROY M, 2006, ENDOCR-RELAT CANCER, V13, P1135
  • [17] c-Myc overexpression and endocrine resistance in breast cancer
    McNeil, Catriona M.
    Sergio, C. Marcelo
    Anderson, Luke R.
    Inman, Claire K.
    Eggleton, Sarah A.
    Murphy, Niamh C.
    Millar, Ewan K. A.
    Crea, Paul
    Kench, James G.
    Alles, M. Chehani
    Gardiner-Garden, Margaret
    Ormandy, Christopher J.
    Butt, Alison J.
    Henshall, Susan M.
    Musgrove, Elizabeth A.
    Sutherland, Robert L.
    [J]. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2006, 102 (1-5) : 147 - 155
  • [18] Associations and interactions between Ets-1 and Ets-2 and coregulatory proteins, SRC-1, AIB1, and NCoR in breast cancer
    Myers, E
    Hill, ADK
    Kelly, G
    McDermott, EW
    O'Higgins, NJ
    Buggy, Y
    Young, LS
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (06) : 2111 - 2122
  • [19] Nonendocrine pathways and endocrine resistance: Observations with antiestrogens and signal transduction inhibitors in combination
    Nicholson, RI
    Hutcheson, IR
    Knowlden, JM
    Jones, HE
    Harper, ME
    Jordan, N
    Hiscox, SE
    Barrow, D
    Gee, JMW
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (01) : 346S - 354S
  • [20] Osborne CK, 2005, CLIN CANCER RES, V11, p865S